DaVita Inc. (NYSE:DVA) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. raised its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,329 shares of the company's stock after buying an additional 14,948 shares during the period. Federated Hermes Inc. owned about 0.18% of DaVita worth $22,033,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Aviva PLC raised its position in shares of DaVita by 427.7% during the 4th quarter. Aviva PLC now owns 27,921 shares of the company's stock worth $4,176,000 after acquiring an additional 22,630 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in DaVita during the fourth quarter worth approximately $2,149,000. World Investment Advisors acquired a new position in shares of DaVita in the 4th quarter valued at $222,000. Huntington National Bank grew its position in shares of DaVita by 17.6% in the 4th quarter. Huntington National Bank now owns 903 shares of the company's stock valued at $135,000 after buying an additional 135 shares during the last quarter. Finally, Kesler Norman & Wride LLC raised its stake in DaVita by 40.2% during the 4th quarter. Kesler Norman & Wride LLC now owns 4,874 shares of the company's stock worth $729,000 after acquiring an additional 1,397 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DVA. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Thursday. Finally, Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $166.33.

DaVita Price Performance

DaVita stock traded down $5.42 during midday trading on Monday, reaching $150.09. The company's stock had a trading volume of 307,014 shares, compared to its average volume of 821,694. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The firm has a market capitalization of $12.01 billion, a PE ratio of 13.97, a P/E/G ratio of 1.07 and a beta of 1.04. The stock's 50 day simple moving average is $152.13 and its 200 day simple moving average is $156.59.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.